CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The T2LEAD project focuses on developing targeted T cell therapies for acute myeloid leukemia. By identifying unique cancer targets, it aims to create safer and more effective chimeric antigen receptor T cells, ultimately improving treatment options for patients.
Acute myeloid leukemia (AML) is a disease with a poor prognosis, especially for such patients either failing initial treatment or relapsing thereafter.
In AML, specific immune cells such as T cells have been proven to bear curative potential in the context of stem cell transplantation but toxicity and therapy failure are frequent.
The use of T cells modified for specificity with chimeric antigen receptors (CAR) has changed the landscape of several blood-borne cancer of the B cell lineage.
In AML…
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Munchen
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
